Ulaner Gary A, Mannelli Lorenzo, Dunphy Mark
aDepartment of Radiology, Memorial Sloan Kettering Cancer Center bDepartment of Radiology, Weill Cornell Medical College, New York, New York, USA.
Nucl Med Commun. 2017 Apr;38(4):306-311. doi: 10.1097/MNM.0000000000000647.
This study aimed to determine whether second-opinion reviews of PET/CT examinations by subspecialists alter reporting of malignant findings.
This IRB-approved study compared 240 fluorine-18 fluorodeoxyglucose PET/CT consecutively dictated reports by two nuclear medicine subspecialists against the original outside institution reports. Subspecialist reviews documented whether malignant findings on the outside report were malignant and noted additional malignant findings not described on the outside report. The final diagnosis of malignancy or benignity was determined by pathology when available, otherwise by imaging follow-up.
A total of 22 findings (in 20 reports) called suspicious/malignant on the outside reports were deemed benign by subspecialist review. A final diagnosis was available for 20 of 22 findings by pathology (n=3) or follow-up imaging (n=17). The subspecialist review was accurate in 20 (100%) of 20 cases where a final diagnosis was available. The subspecialist review called 11 findings (in 11 reports) suspicious/malignant that were not described or deemed benign on the outside reports. Definitive diagnosis was available for 10 of 11 findings by pathology (n=7) or follow-up imaging (n=3). The second-opinion report was accurate in seven (70%) of 10 cases where a final diagnosis was available.
In 31 (13%) of 240 fluorine-18 fluorodeoxyglucose PET/CT examinations performed at an outside institution, subspecialist review resulted in at least one discordant opinion of malignancy. For 28 discrepant cases where a final diagnosis was available, the subspecialist review defined malignancy or benignity correctly in 25 (89%) of 28 cases. This provides evidence for the cost and effort invested in performing second-opinion reviews of PET/CT studies.
本研究旨在确定专科医生对PET/CT检查的二次评估是否会改变恶性病变的报告。
这项经机构审查委员会批准的研究,将两位核医学专科医生对240例氟-18氟脱氧葡萄糖PET/CT连续口述报告与原外部机构报告进行了比较。专科医生评估记录了外部报告中的恶性病变是否为恶性,并指出了外部报告中未描述的其他恶性病变。恶性或良性的最终诊断在有病理结果时由病理确定,否则通过影像随访确定。
外部报告中标记为可疑/恶性的22项结果(来自20份报告)经专科医生评估为良性。22项结果中的20项通过病理(n = 3)或随访影像(n = 17)获得了最终诊断。在可获得最终诊断的20例病例中,专科医生评估有20例(100%)准确。专科医生评估将外部报告中未描述或视为良性的11项结果(来自11份报告)标记为可疑/恶性。11项结果中的10项通过病理(n = 7)或随访影像(n = 3)获得了明确诊断。在可获得最终诊断的10例病例中,二次评估报告有7例(70%)准确。
在外部机构进行的240例氟-18氟脱氧葡萄糖PET/CT检查中,有31例(13%)经专科医生评估产生了至少一项关于恶性病变的不一致意见。对于28例有最终诊断的差异病例,专科医生评估在28例中的25例(89%)中正确界定了恶性或良性。这为对PET/CT研究进行二次评估所投入的成本和精力提供了证据。